Controls should bear the liability, and publishers should reject their ads. Are stakeholders adopting reasonable best practices and controls, in your view . Today that information does not suggest they are doing that. One of the challenges is reluctance to share information among each other. It is isolated now. Again, are recognizing that there is no perfect security in the absence of taking reasonable steps to protect the infrastructure and consumers from harm they should be responsible. How Many Americans do you think know that this problem exists . This information has been kept very quiet. Its been suppressed over years. The executives of some trade organizations have denied it exists publically. We just saw an example of that disputing the malvertising facts. Where did you get them since they dont share your view . We are fortunate. There are many players in the industry that see this as a major issue. This week we had a Dozen Companies come asking for legislation in the ecosystem
That bell being running, then i believe that as youre doing this in terms of leadership function, we run the risk of really losing an enterprise is that the United States essentially pioneered. In terms of another priority that i think youre starting to hear a little bit about, we have to put patients at the center of this. So if you look at the statistics we have 7,000 diseases. Yet, we have treatments for, i believe, dr. Collins, 500 of those. The system is doing its work. Its churning through the science and getting the outcomes to the doors of the fda. The fda is doing its work and then we get some approvals and we put that out into the system. But at the rate were going, i dont think that any of the diseases that were all going to be afflicted with at some point in time really stand a chance of being covered in the near term. So i think the speed issue thats been articulated by many of you is of critical importance. So i think as this group does its work, figuring out what are tho
Hear from here where iavi is and where her partners and prospective from leading pdp in this area. Format well have 30 minutes for dr. Fauci to give us sort after presentation, plenary talk and well move to Mitchell Warren of avac of eight other ten minutes of comments. Margie mcglynn as well eight or ten minutes of comments. Then well open up the pan fell for you to give questions and i will moderate that. A good chance for to you engage with them on discussions where we are with hiv Vaccine Research and where it is coming. So, dr. Faw economy, over fauci, over to you, and thank you for coming. [applause] so i can advance my own slides . There you go. Thank you very much, todd, a real pleasure to be with you here today. Im going to talk a bit about the issue of the role of an hiv vaccine. I want to start off by putting into perspective the concept why we really do need an hiv vaccine despite the spectacular successes and really historic successes well had over the last several years i
This committee. Have i ever heard testimony such as given by you, and by you. I want to thank you to the middle east becaus because the e can get good people together and settle everything. You should settle that and then come back and talk to us more realistically but for you you are what is wrong with this country. And the profit motive is good but only if it is aimed at something for the general benefit of the public and that could be stretched a little bit because the public likes to be entertained. I cant say professional basketball is necessary for the existence in america that some people like it so lets go ahead. But i think in your case you dont have that leeway. Its a matter of dollars for the 256 increase in two years in advertising and can yo then youe only for the adult bought the children when Everything Else has come out of the hearings is otherwise. I think its a dreadful. The head of the National Institute of health says a lack of steady federal funding is hurting effo
Or working with darpa as we are doing and with fda on this toxicity chip. Working on the brain initiative, a new effort which isugoing to be focused between nih and nsf and darpa and a number of private industries and philanthropies trying to make sure these kind of interdisciplinary efforts that jim was talking about are tapped into in every way. We are always looking at that. We are even looking at our peer review system to ask whether while we claim its the best in the world, are we sure about that . And are we sure our peer review system is reflecting the scientific opportunities of 2014 and not some earlier stage, and do we these to rethink about the way in which those peer review panels are established as far as what disciplines they represent. And we have the tools now with various kinds of text mining to really look and see what is going on in science that we might want to make adjustments for. So were pretty bullish about that. Another thing we are doing, again, this reflects